These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 18250228)
41. Effect of Genetic Variability in the Zhang JE; Klein K; Jorgensen AL; Francis B; Alfirevic A; Bourgeois S; Deloukas P; Zanger UM; Pirmohamed M Front Pharmacol; 2017; 8():323. PubMed ID: 28620303 [TBL] [Abstract][Full Text] [Related]
42. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542 [TBL] [Abstract][Full Text] [Related]
43. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236 [TBL] [Abstract][Full Text] [Related]
44. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396 [TBL] [Abstract][Full Text] [Related]
45. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893 [TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics of oral anticoagulants. Daly AK; King BP Pharmacogenetics; 2003 May; 13(5):247-52. PubMed ID: 12724615 [TBL] [Abstract][Full Text] [Related]
47. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population. Chan SL; Goh BC; Chia KS; Chuah B; Wong A; Lim R; Lee SC Thromb Haemost; 2011 Jun; 105(6):1100-2. PubMed ID: 21475774 [No Abstract] [Full Text] [Related]
48. Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses. Moon JY; Lee KE; Chang BC; Jeong E; Jeong H; Gwak HS Pharmacogenet Genomics; 2015 Jan; 25(1):38-40. PubMed ID: 25356900 [TBL] [Abstract][Full Text] [Related]
49. Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long-term implications for bone development and vascular health. Kampouraki E; Avery PJ; Biss T; Kamali F Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521079 [TBL] [Abstract][Full Text] [Related]
50. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359 [TBL] [Abstract][Full Text] [Related]
51. Association Between the Geng H; Li B; Wang Y; Wang L Genet Test Mol Biomarkers; 2019 May; 23(5):342-347. PubMed ID: 30932691 [No Abstract] [Full Text] [Related]
53. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese. Hu BC; Li Y; Li FH; Zhang Y; Sheng CS; Fan HQ; Wang JG J Hypertens; 2011 Mar; 29(3):501-8. PubMed ID: 21150635 [TBL] [Abstract][Full Text] [Related]
54. In silico pharmacogenetics of warfarin metabolism. Guo Y; Weller P; Farrell E; Cheung P; Fitch B; Clark D; Wu SY; Wang J; Liao G; Zhang Z; Allard J; Cheng J; Nguyen A; Jiang S; Shafer S; Usuka J; Masjedizadeh M; Peltz G Nat Biotechnol; 2006 May; 24(5):531-6. PubMed ID: 16680137 [TBL] [Abstract][Full Text] [Related]
55. Genetic variation in the human cytochrome P450 supergene family. Fujikura K; Ingelman-Sundberg M; Lauschke VM Pharmacogenet Genomics; 2015 Dec; 25(12):584-94. PubMed ID: 26340336 [TBL] [Abstract][Full Text] [Related]
56. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519 [TBL] [Abstract][Full Text] [Related]
57. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499 [TBL] [Abstract][Full Text] [Related]
58. Estimation of the warfarin dose with clinical and pharmacogenetic data. ; Klein TE; Altman RB; Eriksson N; Gage BF; Kimmel SE; Lee MT; Limdi NA; Page D; Roden DM; Wagner MJ; Caldwell MD; Johnson JA N Engl J Med; 2009 Feb; 360(8):753-64. PubMed ID: 19228618 [TBL] [Abstract][Full Text] [Related]
59. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005 [TBL] [Abstract][Full Text] [Related]